Back to search results
NCT05341986

Optimizing Stroke Prophylaxis of Acute Atrial Fibrillation With an Electronic Clinical Decision Support Tool

Enrolling by Invitation
NAAges 18+Interventional
Oregon Health and Science University
~36 participants
Updated 2025-03-20 on ClinicalTrials.gov
What's tested:Clinical Decision Support (CDS) tool

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of patients appropriately prescribed OACs after CDS tool implementation.
Measured over through study completion, up to 4 years

Conditions

Atrial Fibrillation

Explore related trials

Atrial Fibrillation

Where it's being run

1 sites across 1 states
Oregon1

Study leadership

  • Bory Kea, MD, MCR · PRINCIPAL_INVESTIGATOR · Oregon Health and Science University

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

A diagnosis of atrial fibrillation or paroxysmal atrial fibrillation (ICD-10 I48.0, I48.1, I48.9) during an ED visit with start dates between 1/11/2022 and 12/31/2025 within the patient's age \>18 years.

Exclusion

Valvular disease, pregnancy, large esophageal varices, thrombocytopenia, severe or uncontrolled bleeding, severe liver or kidney disease, major surgery within 72 hours; OR
Recent brain, eye or spinal cord injury or surgery; OR
ED stroke, death or hospitalization at index visit; OR
Patient transferred from another hospital (to ensure availability of index ED visit data); OR
Left against medical advice; OR
Evidence of non-OAC naïve patient:
OAC prescribed in the prior 3mo to index ED visit; OR
Being managed by an anticoagulation clinic (ACC);

What this trial measures

  • Number of patients appropriately prescribed OACs after CDS tool implementation.through study completion, up to 4 years

    The primary outcome is the number of patients appropriately prescribed OACs after CDS tool implementation.